Patents by Inventor Marcia Gallagher

Marcia Gallagher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11865343
    Abstract: Methods for treating post-traumatic stress disorder (PTSD) and/or for reducing a risk associated with developing PTSD in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with PTSD as well as an increased risk of developing PTSD following a traumatic event. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a PTSD status in the patient. Other aspects are directed to reducing a likelihood of developing PTSD in patients presenting one or more PTSD risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's PTSD status or risk of developing PTSD. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Grant
    Filed: November 1, 2021
    Date of Patent: January 9, 2024
    Assignee: Medtronic Ireland Manufacturing Unlimited Company
    Inventors: Marcia Gallagher, Douglas A. Hettrick
  • Publication number: 20220054840
    Abstract: Methods for treating post-traumatic stress disorder (PTSD) and/or for reducing a risk associated with developing PTSD in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with PTSD as well as an increased risk of developing PTSD following a traumatic event. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a PTSD status in the patient. Other aspects are directed to reducing a likelihood of developing PTSD in patients presenting one or more PTSD risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's PTSD status or risk of developing PTSD. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 24, 2022
    Inventors: Marcia Gallagher, Douglas A. Hettrick
  • Patent number: 11160982
    Abstract: Methods for treating post-traumatic stress disorder (PTSD) and/or for reducing a risk associated with developing PTSD in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with PTSD as well as an increased risk of developing PTSD following a traumatic event. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a PTSD status in the patient. Other aspects are directed to reducing a likelihood of developing PTSD in patients presenting one or more PTSD risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's PTSD status or risk of developing PTSD. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: November 2, 2021
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Marcia Gallagher, Douglas Hettrick
  • Publication number: 20210169570
    Abstract: Methods for treating depression and for reducing a risk associated with developing depression in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with depression as well as an increased risk of developing depression. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a depression status in the patient. Other aspects are directed to reducing a likelihood of developing depression in patients presenting one or more depression risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's depression status or risk of developing depression. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 10, 2021
    Inventors: Marcia Gallagher, Douglas Hettrick
  • Patent number: 10945788
    Abstract: Methods for treating depression and for reducing a risk associated with developing depression in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with depression as well as an increased risk of developing depression. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a depression status in the patient. Other aspects are directed to reducing a likelihood of developing depression in patients presenting one or more depression risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's depression status or risk of developing depression. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: March 16, 2021
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Marcia Gallagher, Douglas Hettrick
  • Publication number: 20190008583
    Abstract: Methods for treating depression and for reducing a risk associated with developing depression in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with depression as well as an increased risk of developing depression. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a depression status in the patient. Other aspects are directed to reducing a likelihood of developing depression in patients presenting one or more depression risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's depression status or risk of developing depression. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Application
    Filed: July 3, 2018
    Publication date: January 10, 2019
    Inventors: Marcia Gallagher, Douglas Hettrick
  • Publication number: 20190009091
    Abstract: Methods for treating post-traumatic stress disorder (PTSD) and/or for reducing a risk associated with developing PTSD in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with PTSD as well as an increased risk of developing PTSD following a traumatic event. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a PTSD status in the patient. Other aspects are directed to reducing a likelihood of developing PTSD in patients presenting one or more PTSD risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's PTSD status or risk of developing PTSD. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Application
    Filed: July 3, 2018
    Publication date: January 10, 2019
    Inventors: Marcia Gallagher, Douglas Hettrick
  • Publication number: 20070265564
    Abstract: A catheter includes elongate flexible inner and outer tubular lumens having proximal and distal regions, and a plurality of exit markers formed in the proximal region. The inner tubular lumen includes an outer surface, and an inner surface, the inner surface defining a guidewire passageway. The outer tubular lumen includes an elongate, flexible, and substantially transparent outer tubular lumen having an outer surface, and an inner surface surrounding the inner tubular lumen. The exit markers may be formed on the inner tubular lumen outer surface or on the outer tubular lumen inner surface, the exit markers being visible to the naked eye through the substantially transparent outer tubular lumen outer surface. The exit markers may also be integrally formed from a polymer that forms a portion of the proximal region of the outer tubular lumen or the inner tubular lumen.
    Type: Application
    Filed: May 15, 2006
    Publication date: November 15, 2007
    Applicant: Medtronic Vascular, Inc.
    Inventors: Aoifa Daly, Luke Hughes, Marcia Gallagher